HAS3 and neoplasm: To further validate the broad applicability of CAF-targeted HA degradation across diverse tumor types, we assessed TAVO423 in a pancreatic cancer model employing BxPC-3 cells engineered to overexpress hyaluronan synthase 3 (BxPC-3-HAS3).